Szczepionka Pfizer/Biotech u osób w wieku 12-15 lat – wyniki badania

Robert W. Frenck, i wsp. Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. N Engl J Med 2021 online

Conclusions: The BNT162b2 vaccine in 12-to-15-year-old recipients had a favorable safety profile, produced a greater immune response than in young adults, and was highly effective against Covid-19.

27 maja 2021

0 replies on “Szczepionka Pfizer/Biotech u osób w wieku 12-15 lat – wyniki badania”